menu
    • menu
    [{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"Atropine","moa":"||mAChR-M1\/M2\/M3","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Kindeva Drug Delivery","amount2":0.13,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0.13,"dosageForm":"Injection","sponsorNew":"Kindeva Drug Delivery \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"15","companyTruncated":"Kindeva Drug Delivery \/ U.S. Department of Health and Human Services"},{"orgOrder":0,"company":"Aspen API","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Acetylcysteine","moa":"Free radical","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Aspen API","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aspen API \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Aspen API \/ Glenmark Pharmaceuticals"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aspen API

                            Netherlands
                            TIDES USA
                            Booth #27, Level 2
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothAspen API. More than just an API™

                            Lead Product(s) : Acetylcysteine

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved FDF

                            Sponsor : Glenmark Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Glenmark Acquires & Launches Acetylcysteine Injection 6gm/30mL Single-Dose Vials

                            Details : Glenmark has acquired generic version of Acetadote (acetylcysteine) injection from Aspen Pharma. It is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury.

                            Product Name : Acetadote-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 03, 2025

                            Lead Product(s) : Acetylcysteine

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved FDF

                            Sponsor : Glenmark Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            Aspen API Comapny Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kindeva Drug Delivery

                            U.S.A arrow
                            ATTD
                            Not Confirmed

                            Kindeva Drug Delivery

                            U.S.A arrow
                            ATTD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine,Pralidoxime Chloride

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved FDF

                            Sponsor : U.S. Department of Health and Human Services

                            Deal Size : $129.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Kindeva Secures $129M SNS Contract for Nerve Agent Antidote

                            Details : The funding aims to advance the the manufacturing of DuoDote (atropine and pralidoxime chloride). It is indicated for the treatment of poisoning by organophosphorus nerve agents.

                            Product Name : Duodote

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 16, 2025

                            Lead Product(s) : Atropine,Pralidoxime Chloride

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved FDF

                            Sponsor : U.S. Department of Health and Human Services

                            Deal Size : $129.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth